Molecular engineering of nanobodies as tools in allergology: diagnostics and beyond

被引：0
作者：
Baunvig Aagaard J. [1 ]
Ravn Ballegaard A.-S. [1 ]
Ommen Andersen P. [1 ]
Spillner E. [1 ]
机构：
[1] Immunological Biotechnology, Department of Biological and Chemical Engineering, Aarhus University, Gustav Wieds Vej 10, Aarhus C
来源：
Allergo Journal International | 2023年 / 32卷 / 7期
关键词：
D O I：
10.1007/s40629-023-00261-w
中图分类号：
学科分类号：
摘要：
Background: Molecular technologies have paved the way to improved understanding of allergic diseases in many ways, ranging from molecular allergens to tailor-made tools for analytical, diagnostic, and therapeutic purposes. Engineering of such molecules has become a mainstay in most biotechnical and biomedical areas. A not so new kid on the block is the nanobody, a single-domain antibody obtained from primarily camelid species. Despite their large promise and potential, it took nanobodies a long time to also enter the stage in allergology. Methods: This review summarizes the state of the art and the feasibility of engineering nanobody-based tools for applications in allergology. Results: In recent years, nanobodies with specificity for allergens have been increasingly generated. In parallel, their molecular engineering has enabled the development of derivatives that offer many advantages compared to standard antibody approaches. Hence, different application forms of nanobody-based molecules have been developed and reported in proof-of-concept studies. Discussion: Recent studies give a first glimpse of the future possibilities of nanobody technologies in a complex system such as allergic diseases. It has become clear that the simplicity of the approaches as compared to regular antibody technologies will both broaden and deepen the scope of applications in allergology. © 2023, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
引用
收藏
页码：240 / 250
页数：10
相关论文
共 76 条
[1]  
Finkelman F.D., Boyce J.A., Vercelli D., Rothenberg M.E., Key advances in mechanisms of asthma, allergy, and immunology in 2009, J Allergy Clin Immunol, 125, pp. 312-318, (2010)
[2]  
Chang T.W., The pharmacological basis of anti-IgE therapy, Nat Biotechnol, 18, pp. 157-162, (2000)
[3]  
Gould H.J., Sutton B.J., IgE in allergy and asthma today, Nat Rev Immunol, 8, pp. 205-217, (2008)
[4]  
Clement M.J., Fortune A., Phalipon A., Marcel-Peyre V., Simenel C., Imberty A., Et al., Toward a better understanding of the basis of the molecular mimicry of polysaccharide antigens by peptides: the example of Shigella flexneri 5a, J Biol Chem, 281, pp. 2317-2332, (2006)
[5]  
Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Et al., Naturally occurring antibodies devoid of light chains, Nature, 363, pp. 446-448, (1993)
[6]  
Ward E.S., Gussow D., Griffiths A.D., Jones P.T., Winter G., Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli, Nature, 341, pp. 544-546, (1989)
[7]  
Konning D., Zielonka S., Grzeschik J., Empting M., Valldorf B., Krah S., Et al., Camelid and shark single domain antibodies: structural features and therapeutic potential, Curr Opin Struct Biol, 45, pp. 10-16, (2016)
[8]  
Platts-Mills T.A., Hilger C., Jappe U., van Hage M., Gadermaier G., Spillner E., Et al., Carbohydrate epitopes currently recognized as targets for IgE antibodies, Allergy, 76, pp. 2383-2394, (2021)
[9]  
Pons L., Chery C., Romano A., Namour F., Artesani M.C., Gueant J.L., The 18 kDa peanut oleosin is a candidate allergen for IgE-mediated reactions to peanuts, Allergy, 57, 72, pp. 88-93, (2002)
[10]  
Blank S., Seismann H., Michel Y., McIntyre M., Cifuentes L., Braren I., Et al., Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts, Allergy, 66, pp. 1322-1329, (2011)
12345678